TCR1188-ABC Cells in KRAS-mutated Cancers

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 2042 → Nov 2042
See other at-risk trials from University of Pennsylvania

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 2026 to Dec 2026
    • Primary and study completion pushed from Jul 2042 to Nov 2042
    • Eligibility criteria expanded, about 38 words
  2. Start date: Jul 2026 to Aug 2026v3
  3. Recruitment opened
    • Eligibility criteria expanded, about 14 words
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Pennsylvania
460 trials monitored
See 32 trials at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,085 trials monitored
See 178 trials at risk
and 2 more diseases
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Trial Details
NCT Number NCT07594067
Lead Sponsor University of Pennsylvania
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
Related terms Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Colorectal Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov